Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gilead Sciences’ Truvada recommended for pre-exposure prophylaxis indication

Gilead Sciences’ Truvada recommended for pre-exposure prophylaxis indication

26th July 2016

Gilead Sciences has announced that its HIV therapy Truvada has been recommended for EU approval as a pre-exposure prophylaxis tool.

The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion on the company's Type II variation application for once-daily Truvada, in combination with safer sex practices, to reduce the risk of sexually acquired HIV-1 infection among uninfected adults at high risk.

Worldwide clinical guidelines support the use of pre-exposure prophylaxis methods in combination with existing prevention measures such as condoms as a means of curbing the spread of HIV.

Two large placebo-controlled trials of Truvada have demonstrated the potential benefits it can offer in this indication.

Professor Jean-Michel Molina of the Hopital Saint Louis and University of Paris said: "The CHMP's opinion moves the medical community closer to being able to offer an additional HIV prevention tool to people at high risk of HIV acquisition across the entire EU."

Truvada was originally approved in Europe in 2005 for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. It is currently the most prescribed antiretroviral medicine in Europe as part of combination therapy.ADNFCR-8000103-ID-801822465-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.